Abbott lowers earnings forecast after $21B Exact Sciences buy
CEO Robert Ford said the companies are a good cultural fit and he expects demand for Exact’s colon cancer screening test to increase.
Abbott lowers earnings forecast after $21B Exact Sciences buy Read More »
